Want to see DMAC full AI Analyst Report?
DMAC Stock Chart & Stats
$6.70
$0.07(0.97%)
At close: 4:00 PM EDT
$6.70
$0.07(0.97%)
Day’s Range― - ―
52-Week Range$5.25 - $10.42
Previous CloseN/A
Volume23.88K
Average Volume (3M)217.65K
Market Cap
$424.40M
Enterprise Value$336.10M
Total Cash (Recent Filing)$43.50M
Total Debt (Recent Filing)$185.00K
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Nov 18, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding53,925,697
10 Day Avg. Volume239,862
30 Day Avg. Volume217,652
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)6.66
Price to Sales (P/S)0.00
P/FCF Ratio-12.85
Enterprise Value/Market Cap0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.97
Forecast
1Y Price Target
$12.00Price Target Upside79.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.78
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ProgressAdvancing ReMEDy2 toward its interim analysis provides a defined clinical decision point for DM199 in acute ischemic stroke. Broad enrollment across roughly 70 sites and multiple countries supports trial execution, while a meaningful readout could clarify the program’s development path.
Pipeline ExpansionDM199 is being evaluated across stroke, preeclampsia, and fetal growth restriction, expanding its potential clinical utility beyond one indication. Statistically significant blood-pressure reductions and continued pregnancy-program development strengthen the rationale for broader pipeline value.
Low LeverageVery low leverage preserves financial flexibility while the company funds clinical development. A meaningful asset and equity base reduces immediate balance-sheet pressure and gives management more room to prioritize trials, regulatory work, and other development activities.
Bears Say
Pre-revenue LossesWith no marketed-product revenue and sustained operating losses, Diamedica remains dependent on external financing or future clinical and commercial success. Persistent losses limit self-funding capacity and make the investment case highly dependent on development milestones.
Rising Cash BurnNegative free cash flow has worsened over time and is largely reflected in cash rather than accounting adjustments. Continued spending at this level increases future funding needs, potentially forcing financing before revenue generation and creating pressure on capital allocation.
Development ComplexityExtra regulatory studies add cost and extend the path toward a potential U.S. IND, while possible receptor desensitization narrows the usable dose range. These factors can complicate trial design, slow development decisions, and increase execution risk across indications.
Diamedica Therapeutics News
DMAC FAQ
What was Diamedica Therapeutics Inc’s price range in the past 12 months?
Diamedica Therapeutics Inc lowest stock price was $5.25 and its highest was $10.42 in the past 12 months.
What is Diamedica Therapeutics Inc’s market cap?
Diamedica Therapeutics Inc’s market cap is $424.40M.
When is Diamedica Therapeutics Inc’s upcoming earnings report date?
Diamedica Therapeutics Inc’s upcoming earnings report date is Nov 18, 2026 which is in 28 days.
How were Diamedica Therapeutics Inc’s earnings last quarter?
Diamedica Therapeutics Inc released its earnings results on Aug 10, 2026. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.201 by $0.011.
Is Diamedica Therapeutics Inc overvalued?
According to Wall Street analysts Diamedica Therapeutics Inc’s price is currently Undervalued.
Does Diamedica Therapeutics Inc pay dividends?
Diamedica Therapeutics Inc does not currently pay dividends.
What is Diamedica Therapeutics Inc’s EPS estimate?
Diamedica Therapeutics Inc’s EPS estimate is -0.21.
How many shares outstanding does Diamedica Therapeutics Inc have?
Diamedica Therapeutics Inc has 53,925,697 shares outstanding.
What happened to Diamedica Therapeutics Inc’s price movement after its last earnings report?
Diamedica Therapeutics Inc reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.201. Following the earnings report the stock price went up 3.308%.
Which hedge fund is a major shareholder of Diamedica Therapeutics Inc?
Currently, no hedge funds are holding shares in DMAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Diamedica Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (79.10% Upside)
$12.00 (79.10% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.06%
12-Months-Change
Fundamentals
Return on Equity
-77.68%
Trailing 12-Months
Asset Growth
43.00%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Diamedica Therapeutics Inc
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
DMAC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted meaningful clinical progress: completion of the first FGR cohort, a supportive Part 1a preeclampsia data set with statistically significant blood pressure reductions and improved uterine perfusion signals, regulatory advances in Canada and planned expansions, and continued progress toward the ReMEDy2 interim analysis with broad site coverage. Financially, the company maintains a cash runway through 2027 but is experiencing a notable decline in cash and working capital versus year-end and materially higher R&D spend and operating cash burn. Operational and regulatory headwinds include enrollment variability, additional rat studies required for a U.S. IND, and a nonlinear dose-response that constrains higher-dose strategies. Overall, the positive clinical momentum and defined regulatory paths outweigh the financing and operational challenges in the near term.View all DMAC earnings summariesDMAC Stock 12 Month Forecast
Average Price Target
$12.00
▲(79.10% Upside)
Technical Analysis
Tvardi Therapeutics
―
Capricor Therapeutics
―
Rocket Pharmaceuticals
―
Benitec Biopharma
―
Annexon Biosciences
―
Ownership Overview
17.81% Insiders
2.85% Mutual Funds
― Other Institutional Investors
75.37% Public Companies and
Individual Investors